SCHEMBL5010558

SCHEMBL5010558

CS(=O)(=O)Nc1ccccc1CNC(=O)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 4/20 0.52
RCE1 Q9Y256 1/20 0.52
HPGD P15428 4/20 0.43
PPARG P37231 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
HSD17B10 Q99714 1/20 0.39
NTRK1 P04629 5/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5013511 0.88 KMT2A (0.44) ALDH1A1KDM4ERCE1HPGDPPARG
SCHEMBL5008235 0.88 PPARG (0.44) ALDH1A1KDM4ERCE1PPARGMEN1
SCHEMBL14587822 0.86 PPARG (0.43) ALDH1A1KDM4ERCE1PPARGMEN1
SCHEMBL5008267 0.86 PPARG (0.45) ALDH1A1HPGDPPARGMEN1KMT2A
SCHEMBL5010568 0.86 NPC1 (0.46) ALDH1A1KDM4ERCE1PPARGMEN1
Hydrochloric Acid SCHEMBL5012282 0.86 PPARG (0.42) ALDH1A1KDM4ERCE1PPARGMEN1
SCHEMBL5010356 0.85 PPARG (0.50) ALDH1A1KDM4EHPGDPPARGHTT
SCHEMBL5009713 0.84 NTRK1 (0.44) ALDH1A1HPGDPPARGMEN1KMT2A
SCHEMBL5008178 0.84 PPARG (0.45) PPARGHTTNPC1RAB9ACYP2C19
SCHEMBL5013521 0.83 PPARG (0.47) ALDH1A1PPARGCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ALDH1A1 1278/4885KDM4E 3446/4885RCE1 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.